Unicancer
Marie Deniau is an accomplished healthcare leader with extensive experience in various management roles within the industry. Currently serving as a RWD/RWE project leader at Unicancer since September 2021, Marie oversees a multicentric RWD platform in oncology involving over 50 hospitals. Previous positions include Deputy Hospital Director at CMC Ambroise Paré and Patient Journey Director at ELSAN, focusing on enhancing patient experiences and operational efficiencies. With a solid foundation in sales and consulting, Marie has held leadership roles in companies such as VERLINGUE and Cegedim, consistently driving business growth and developing tailored solutions for the pharmaceutical sector. Academic credentials include degrees from Sciences Po, University of Paris I: Panthéon-Sorbonne, and OMNES Education, emphasizing economics, finance, and healthcare management.
This person is not in any teams
Unicancer
UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries